EMB-07 combo for aggressive B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination treatment for people with aggressive B-cell non-Hodgkin lymphoma, including those with relapsed/refractory disease or newly diagnosed high-risk cases. It aims to see if EMB-07 combined with other drugs is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your overall health should be good enough to carry out daily activities with little help (ECOG score 0-1 or 0-2, depending on the phase).
- You must have a type of aggressive B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) or transformed follicular lymphoma that has come back or not responded to treatment (for Cohort A) or is newly diagnosed with certain risk features (for Cohort B).
- You cannot have active brain or spinal cord involvement from your lymphoma.
- You must not have had certain prior treatments that could interfere with the study drugs.
- Your heart, liver, and kidney function must be adequate, and you must not have serious infections or other uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
This study tests a new drug combined with standard chemotherapy and immune therapy for people with diffuse large B-cell lymphoma. The goal is to see if the combination is safe and helps shrink or control the cancer.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Hear when a new Combination Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.